Effects of Semaglutide on Chronic Kidney Disease in Patients with Type 2 Diabetes.
The DOI matches its Crossref record; 23 of the 23 references it cites were found in a registry or an index.
Abstract
Semaglutide in type 2 diabetes with chronic kidney disease.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Furthermore, semaglutide also significantly reduced the rate of eGFR decline (annual slope difference 1•16 mL/min per 1•73 m², 0•86-1•47), MACE (HR 0•82, 0•68-0•98), and all-cause mortality (HR 0•80, 0•67-0•95)”
From GLP-1 receptor agonists and next-generation incretin-based medications: metabolic, cardiovascular, and renal benefits (2026) · cites this paper as [26]
In the citing paper
“Treatment with injectable semaglutide 1 mg once weekly reduced the relative risk for the composite primary outcome (ie, ≥50% eGFR decline, eGFR <15 mL/min per 1•73 m², dialysis or transplant, or death due to kidney disease or cardiovascular disease) by 24% compared with placebo (HR 0•76, 0•66-0•88).26”
From GLP-1 receptor agonists and next-generation incretin-based medications: metabolic, cardiovascular, and renal benefits (2026) · cites this paper as [26]
In the citing paper
“Moreover, the GLP-1 receptor agonist, semaglutide reduced the risk of a composite kidney end point in a dedicated kidney outcome trial.11”
From The Effect of Retatrutide on Kidney Parameters in Participants With Type 2 Diabetes Mellitus and/or Obesity (2025) · cites this paper as [11]
In the citing paper
“semaglutide can reduce the progression of chronic kidney disease in patients with and without diabetes and even in those taking SGLT2 inhibitors [12–14].”
From New drugs for the treatment of obesity: do we need approaches to preserve muscle mass? (2025) · cites this paper as [13]
In the citing paper
“Once-weekly treatment with 1 mg semaglutide reduced the risk of the primary composite outcome by 24% and delayed the progression of kidney dysfunction over a period of 4 years (75).”
From Antiinflammatory actions of glucagon-like peptide-1–based therapies beyond metabolic benefits (2025) · cites this paper as [75]
35 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
A New Equation to Estimate Glomerular Filtration Rate
Levey, A. S., Stevens, L. A., Schmid, C. H., Zhang, Y. (., Castro, A. F., Feldman, H. I., Kusek, J. W., Eggers, P., Van Lente, F., Greene, T., et al. (2009) · Annals of Internal Medicine · doi:10.7326/0003-4819-150-9-200905050-00006 · Cited by 25,603
KDIGO 2024 clinical practice guideline for the evaluation and management of chronic kidney disease
Stevens, P. E., Ahmed, S. B., Carrero, J. J., Foster, B., Francis, A., Hall, R. K., Herrington, W. G., Hill, G., Inker, L. A., Kazancıoğlu, R., et al. (2024) · Kidney International · doi:10.1016/j.kint.2023.10.018 · Cited by 8,530
Brenner, B. M., Cooper, M. E., de Zeeuw, D., Keane, W. F., Mitch, W. E., Parving, H.-H., Remuzzi, G., Snapinn, S. M., Zhang, Z., & Shahinfar, S. (2001) · New England Journal of Medicine · doi:10.1056/nejmoa011161 · Cited by 7,493
Bikbov, B., Purcell, C. A., Levey, A. S., Smith, M., Abdoli, A., Abebe, M., Adebayo, O. M., Afarideh, M., Agarwal, S. K., Agudelo-Botero, M., et al. (2020) · The Lancet · doi:10.1016/s0140-6736(20)30045-3 · Cited by 6,648
Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy
Perkovic, V., Jardine, M. J., Neal, B., Bompoint, S., Heerspink, H. J. L., Charytan, D. M., Edwards, R., Agarwal, R., Bakris, G., Bull, S., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1811744 · Cited by 6,189
Self-citationLewis, E. J., Hunsicker, L. G., Clarke, W. R., Berl, T., Pohl, M. A., Lewis, J. B., Ritz, E., Atkins, R. C., Rohde, R., & Raz, I. (2001) · New England Journal of Medicine · doi:10.1056/nejmoa011303 · Cited by 5,987
Dapagliflozin in Patients with Chronic Kidney Disease
Heerspink, H. J. L., Stefánsson, B. V., Correa-Rotter, R., Chertow, G. M., Greene, T., Hou, F.-F., Mann, J. F. E., McMurray, J. J. V., Lindberg, M., Rossing, P., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2024816 · Cited by 5,618
Self-citationEffect of finerenone on chronic kidney disease outcomes in type 2 diabetes
Bakris, G. L., Agarwal, R., Anker, S. D., Pitt, B., Ruilope, L. M., Rossing, P., Kolkhof, P., Nowack, C., Schloemer, P., Joseph, A., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2025845 · Cited by 2,935
Self-citationEmpagliflozin in Patients with Chronic Kidney Disease
The EMPA-KIDNEY Collaborative Group (2023) · New England Journal of Medicine · doi:10.1056/nejmoa2204233 · Cited by 2,754
Cardiovascular events with finerenone in kidney disease and type 2 diabetes
Pitt, B., Filippatos, G., Agarwal, R., Anker, S. D., Bakris, G. L., Rossing, P., Joseph, A., Kolkhof, P., Nowack, C., Schloemer, P., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2110956 · Cited by 1,814
Self-citation
Cited by
Items 801–900 of 1,871
Ko, D., Kim, D. H., Tan, F. X. N., Ho, G. J. K., Chandra, R., Xuan, Z. Z., Tham, E. K. J., Tang, N. S. Y., Yang, H. S., Koh, J. W. H., et al. (2026) · Cell Reports Medicine · doi:10.1016/j.xcrm.2026.102614 · Cited by 3
Loh, W. J. (2024) · Current Opinion in Endocrinology Diabetes and Obesity · doi:10.1097/med.0000000000000892 · Cited by 4
Teli, B., Somani, S., Arya, V., Rajput, P. J., Kahale, P., Bharmal, V. S., Shah, S., Patel, V., Ahuja, A., & PATANGE, S. A. (2026) · Cureus · doi:10.7759/cureus.108999 · Cited by 2
Alsheikh, A., Al-Jedai, A. H., Almudaiheem, H., Alaidarous, S. B., Alshehri, A., Elbadawi, H., Alghamdi, S., Aljehani, F., Alobaidi, S. A., Altuwaijri, T. A., et al. (2025) · International Journal of Clinical Medicine · doi:10.4236/ijcm.2025.161004 · Cited by 6
Lehenbauer, K. S., Nelson, A. J., Nodari, S., Sverdlov, A. L., & Harrington, J. (2025) · Heart Failure Reviews · doi:10.1007/s10741-025-10579-y · Cited by 5
Oshima, M., Gosho, M., Iwagami, M., Sugawara, Y., Nagasu, H., Kuwabara, T., Sofue, T., Nakagawa, N., & Miyamoto, Y. (2026) · Clinical and Experimental Nephrology · doi:10.1007/s10157-026-02835-8 · Cited by 2
“For example, the FLOW trial [25] used total eGFR slope as a confirmatory secondary outcome.”
Courtney, L. A., Clements, J. N., Isaacs, D. M., Pitlick, J. M., Reece, S. W., & Whitley, H. P. (2025) · Diabetes & Metabolic Syndrome Clinical Research & Reviews · doi:10.1016/j.dsx.2025.103314 · Cited by 3
Lv, R., Peng, L., Xu, Y., Du, X., Liu, H. X., Wu, H., Zhang, Y., Li, Q., Jiao, X., Piao, C., et al. (2026) · EClinicalMedicine · doi:10.1016/j.eclinm.2026.104045 · Cited by 3
“7,8 However, widespread adoption of peptide-based therapies is hindered by significant limitations.”
InfluentialZhang, W., Stewart, C., Xiao, A., Zhan, Y., Wei, T., Wu, J., Li, L., Zheng, C., Huang, H., & Han, J. (2026) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.5c02439 · Cited by 3
Pharmacogenetics of incretin-based therapies
Yaluri, A. S., Ürgeová, A., Maršálek, M., Javorský, M., & Tkáč, I. (2025) · Postgraduate Medical Journal · doi:10.1093/postmj/qgaf232 · Cited by 3
Vettor, R., Petroni, M. L., Dotan, I., Lalazar, G., Haluzík, M., Spearman, C. W., Dave, J. A., Abaalkhail, F. A., Abusnana, S., Alshehri, A. A., et al. (2026) · Reviews in Endocrine and Metabolic Disorders · doi:10.1007/s11154-026-10027-8 · Cited by 6
“It also lowered the incidence of a composite endpoint, including adverse kidney outcomes and kidney-related or cardiovascular mortality, by 24% in people with CKD and T2D [115].”
Yau, K., Ray, J. G., Jeyakumar, N., Luo, B., Abdullah, S. S., Dixon, S. N., Wing, S. L., Clemens, K. K., Castrillon-Ramirez, F., Udell, J. A., et al. (2025) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2025.09.010 · Cited by 2
Obesity management: a foundational cardiovascular health priority
Ostrominski, J. W., Plutzky, J., Sattar, N. A., Vaduganathan, M., & Aroda, V. R. (2025) · European Journal of Preventive Cardiology · doi:10.1093/eurjpc/zwaf043 · Cited by 4
Panou, T., Gouveri, E., Rizzo, M., Popovic, D. S., & Παπάνας, Ν. (2025) · Frontiers in Clinical Diabetes and Healthcare · doi:10.3389/fcdhc.2025.1657710 · Cited by 5
Dai, J.-W., Lin, Y., Li, X., Tseng, C.-J., Tsai, M., Yang, N., Hung, M., & Chen, T. (2024) · Scientific Reports · doi:10.1038/s41598-024-79255-9 · Cited by 5
Pantazopoulos, D., Vas, P. R. J., Rerkasem, K., & Παπάνας, Ν. (2026) · The International Journal of Lower Extremity Wounds · doi:10.1177/15347346261474199 · Cited by 3
Barenbaum, S. R., Aras, M., Kashyap, S. R., & Aronne, L. J. (2025) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgaf641 · Cited by 2
Fountoulakis, N., Pavlou, P., Stathi, D., Goubar, A., Corcillo, A., Flaquer, M., Ayis, S. A., Gnudi, L., & Karalliedde, J. J. (2026) · Diabetes Obesity and Metabolism · doi:10.1111/dom.70481 · Cited by 3
“We also acknowledge that use of SGLT-2 inhibitors and nsMRA in recent larger clinical trials is also often low; for example, SGLT-2 inhibitor use was 15.6% in FLOW trial [13] and (cid:4) 31% in the recent SURPASS CVOT (MRA use <10% in SURPASS CVOT) [50].”
InfluentialGLP-1 Receptor Agonists for CKD: Remaining Issues or Mission Complete?
Kosjerina, V., & Rossing, P. R. (2025) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2025.03.001 · Cited by 2
Self-citationSellasie, S. W., Pecchioli, C., Cersosimo, K., Nardone, I., Zaccaria, S., Centi, A., Perna, P., Tatangelo, P., Sperti, P., Schifano, G., et al. (2025) · Acta Diabetologica · doi:10.1007/s00592-024-02423-w · Cited by 2
Catanese, B. P., Miller, C., Wolf, M. S., & Edmonston, D. L. (2026) · Journal of the American Society of Nephrology · doi:10.1681/asn.0000001061 · Cited by 3
The GLP-1 RA boom: Trends in publicly subsidised and private access in Australia, 2020-2025Preprint
Falster, M. O., Costa, J. D. O., Milder, T. Y., Carson, J. M., Shadbolt, C., Neuen, B. L., Arnott, C. G., Wilson, A. J., Jun, M., Pratt, N. L., et al. (2025) · medRxiv · doi:10.1101/2025.10.30.25339120 · Cited by 2
Glucagon-like peptide-1 receptor agonists in patients with anthracycline related cardiac dysfunction
Scalia, I. G., Ibrahim, R., Abdelnabi, M. H., Pham, H. N., Farina, J., Pereyra, M., Lee, K. S. S., Tamarappoo, B. K., Arsanjani, R., & Ayoub, C. (2025) · Cardio-Oncology · doi:10.1186/s40959-025-00381-y · Cited by 6
Shen, J., Sarwal, A., Singh, R., Hartsell, S. E., Wei, G., Nevers, M. R., Christensen, J. C., Takyi, A., Katkam, N., Derington, C. G., et al. (2025) · Diabetes Obesity and Metabolism · doi:10.1111/dom.16207 · Cited by 3
“33,34 In the current study, 98.7% of new users of GLP-1RA were initiated on liraglutide, 6 dulaglutide 5 and semaglutide 7 – 9 that have demonstrated cardiovascular or kidney protective effects.”
InfluentialGhosal, S., & Ghosal, A. (2025) · Diabetes Metabolic Syndrome and Obesity · doi:10.2147/dmso.s575790 · Cited by 2
Renin-Angiotensin Aldosterone System Modulation and Cardiovascular-Kidney-Metabolic HealthPreprint
Mochel, J. P. (2024) · Preprints.org · doi:10.20944/preprints202406.2075.v1 · Cited by 1
Napoli, M. D., Morton, K., Evensky, C. H., Yoshida, C. T., Baimas‐George, M. R., Castle, R., Kennealey, P. T., Nydam, T. L., & Choudhury, R. A. (2026) · The American Journal of Surgery · doi:10.1016/j.amjsurg.2026.117027 · Cited by 2
Implementing a model of integrated CKD management between primary and secondary care
Jones, P., O’Keeffe, H., Major, R., Ritchie, J. P., Sanganee, N., Sinha, S., & Burton, J. O. (2025) · Clinical Kidney Journal · doi:10.1093/ckj/sfaf335 · Cited by 2
Kidney-Vascular Metabolic Crosstalk: Altered Lipoproteins in CKD
Saum, K. L., Pennathur, S., & Kanter, J. E. (2026) · Circulation Research · doi:10.1161/circresaha.126.327361 · Cited by 3
Glucagon-Like Peptide 1 Receptor Agonists and Cardiovascular Disease
Ibe, T., & Borlaug, B. A. (2025) · Annual Review of Medicine · doi:10.1146/annurev-med-043024-011141 · Cited by 4
Combination therapy in preclinical studies and clinical trials: Evidence, gaps and the path ahead
Li, S., Dreher, L., Danser, A. H. J., & Wenzel, U. O. (2025) · British Journal of Pharmacology · doi:10.1111/bph.70140 · Cited by 2
“For instance, SGLT2 inhibition on top of aldosterone blockade lowers the risk of hyperkalaemia that is associated with the latter (Tuttle et al., 2024).”
Morieri, M. L., Vedovato, M., Bonora, B. M., Fioretto, P., & Fadini, G. P. (2026) · Diabetes Obesity and Metabolism · doi:10.1111/dom.70445 · Cited by 2
“11 Thus, the latest ADA guidelines recommend, for people with type 2 diabetes and CKD, SGLT2i or semaglutide as first-line therapies.”
Touzot, M., Voican, A., Potier, L., Beaussier, H., Cachanado, M., Sacco, E., Châtellier, G., Ridel, C., Ureña, P., Banu, I., et al. (2025) · Diabetes Obesity and Metabolism · doi:10.1111/dom.16484 · Cited by 4
Marshall, W. R., McDonnell, T., Green, D., Sinha, S., & Kalra, P. A. (2026) · Kidney International Reports · doi:10.1016/j.ekir.2026.106592 · Cited by 9
Hung, T., Lin, T., Liou, Y., Lin, T., Hsu, Y., Lin, L., & Wang, M. (2025) · Journal of Internal Medicine · doi:10.1111/joim.20112 · Cited by 2
“Similarly, glucagon-like peptide-1 receptor agonists (GLP-1 RAs), another newer class of antidiabetic medications, have been demonstrated to have renal protective effects in randomized controlled trials (RCTs) [13, 14].”
Dilaver, R. G., Afşar, R. E., Crescenzi, R. L., Gamboa, J. L., & Ikizler, T. A. (2025) · medRxiv · doi:10.1101/2025.03.19.25324266 · Cited by 2
Hung, K., Chang, L.-C., Tan, P.-H., Hsu, C., Lai, Y., Wu, J., & Chen, I. (2025) · Obesity Surgery · doi:10.1007/s11695-025-08436-w · Cited by 4
“Although cumulative evidence supports the long-term renoprotective effects of GLP-1-RAs on cardiovascular and renal outcomes [17 –20 ], their impact on the risk of postop - erative AKI in this patient population remains unclear.”
Xiang, Y., Liu, Z., Feng, J.-K., Qin, Y., Yu, H., Cheng, Y., Chen, G., Wu, J., Huang, T., Tang, Y. C., et al. (2026) · Gut · doi:10.1136/gutjnl-2026-338462 · Cited by 4
Takahashi, R., Obi, Y., Kalantar‐Zadeh, K., & Kovesdy, C. P. (2025) · Current Opinion in Nephrology & Hypertension · doi:10.1097/mnh.0000000000001131 · Cited by 5
Oral Health Considerations and Dental Management Guidelines for Semaglutide Medications
Kofman, K., & Ouanounou, A. (2026) · Canadian Journal of Diabetes · doi:10.1016/j.jcjd.2026.03.008 · Cited by 6
Iwasaki, Y., Shimada, T., Kishimori, T., Kato, T., Koike, J., Matsumoto, T., Yagi, T., & Okada, M. (2025) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2025.113072 · Cited by 2
Orforglipron, an Oral GLP-1 Receptor Agonist, in Early Type 2 Diabetes
(2025) · New England Journal of Medicine · doi:10.1056/nejmc2515117 · Cited by 2
Challenges in Modelling the Cost Effectiveness of Pharmacotherapies for Obesity
Pennington, B., Cummins, E., Chandler, A., & Fotheringham, J. (2025) · PharmacoEconomics · doi:10.1007/s40273-025-01520-0 · Cited by 4
“Evidence for GLP-1 therapies in people with obesity (with and without diabetes) indicates they may impact specific non-weight-related endpoints [44, 47].”
Liu, L., Chen, J., Zhang, X., Zhu, S., Dai, T., Wu, Q., & Fang, Y. (2025) · Diabetology & Metabolic Syndrome · doi:10.1186/s13098-025-02064-1 · Cited by 3
“…Additionally, GLP-1 RAs have been shown to slow the decline in estimated glomerular filtration rate (eGFR) and the progression of albumin-uria, providing significant renal benefits for patients with T2DM and CKD, reducing the risk of composite renal endpoints by 24% on top of standard care [42].”
Kim, Y. C., Meng, C., Kanoo, S., Thomson, S. C., Karihaloo, A., & Vallon, V. (2026) · American Journal of Physiology-Renal Physiology · doi:10.1152/ajprenal.00109.2026 · Cited by 4
Schreier, L. P., Zhu, Z., Kusunoki, Y., Li, C., Ku, J., Klaus, M., & Anders, H. (2025) · Kidney360 · doi:10.34067/kid.0000000747 · Cited by 2
What is the Role of Primary Prevention of Obesity in an Age of Effective Pharmaceuticals?
Gómez‐Martín, M., Canfell, O. J., Chai, L. K., Jansson, A. K., Littlewood, R., Sullivan, C. M., Power, D. D., Clarke, E. D., Ells, L. J., de Vlieger, N., et al. (2025) · Current Obesity Reports · doi:10.1007/s13679-025-00632-0 · Cited by 4
“In recent years, there has been rapid progression in pharmacotherapies, including those initially designed for treatment of diabetes now showing efficacy in the treatment of obesity and obesity-related diseases [10–13].”
Obesity-related glomerulopathy: a lesser known complication of obesity
Sharma, S., Sharma, A., Kapoor, N., Sharma, N., Saravanan, P., & Kalra, S. (2025) · Current Opinion in Endocrinology Diabetes and Obesity · doi:10.1097/med.0000000000000930 · Cited by 4
Luyckx, V. A., & Taal, M. W. (2025) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfaf228 · Cited by 2
Górriz, J. L., Gil, F. A., López, M. A. B., Soto, A. B., Cabrera, F. J. C., Cisneros, A., Guerrero, S. C., Conejos, M. D., Cabello, I. E., Planelles, M., et al. (2025) · Nefrología (English Edition) · doi:10.1016/j.nefroe.2025.05.001 · Cited by 3
McEwan, P. C., FOOS, V., Roberts, G. M., Jenkins, R. L., Evans, M., Wheeler, D. C., & Chen, J. (2025) · Diabetes Obesity and Metabolism · doi:10.1111/dom.16141 · Cited by 3
Cardiovascular Risk Reduction With GLP-1 RA Drugs
Pigeyre, M., & Gerstein, H. C. (2026) · Circulation · doi:10.1161/circulationaha.126.079319 · Cited by 4
Jialal, I., & Olatunbosun, S. T. (2025) · Journal of Clinical Medicine · doi:10.3390/jcm14103335 · Cited by 2
Damman, K., ter Maaten, J. M., Mayne, K. J., Bolignano, D., Brown, E. M., da Costa, B. R., Dagre, A. G., Gansevoort, R. T., Gavina, C., Goette, A., et al. (2026) · European Heart Journal · doi:10.1093/eurheartj/ehag098 · Cited by 34
Amycretin in obesity: Mechanisms, clinical efficacy, and future perspectives
Fu, L., Ding, R., Xu, G., Hu, J., & Yang, P. C. (2026) · Metabolism · doi:10.1016/j.metabol.2026.156594 · Cited by 6
Effectiveness of Semaglutide in Overweight or Obese Patients With IgA Nephropathy Without Diabetes
Si, F., Tang, C., Chen, P., Hou, W., Yang, H., Lv, J., Shi, S., Zhou, S., Liu, L., & Zhang, H. (2025) · Nephrology · doi:10.1111/nep.70023 · Cited by 2
Malas, K., Kazmi, S., Kang, Y. M., & McGuire, D. K. (2025) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2025.2504702 · Cited by 4
Dahl, J. N., Nissen, L., Nielsen, M. B., Rasmussen, L. D., Søby, J. H., Birn, H., Bøttcher, M., & Winther, S. (2025) · European Journal of Preventive Cardiology · doi:10.1093/eurjpc/zwaf218 · Cited by 2
Dufour, I., Regemorter, E. V., Kanaan, N., Buemi, A., Darius, T., Mourad, M., Goffin, E. J., Jadoul, M. Y., Devresse, A., & Gillion, V. (2025) · Transplantation · doi:10.1097/tp.0000000000005186 · Cited by 2
“112 This is a phase 3 clinical trial involving 3533 patients with T2D and moderate-severe CKD (eGFR 25–75 mL/min/1.73 m 2 and urine albumin-creatinine ratio [UACR] of 300– 5000 mg/g), randomized to either semaglutide (1.0 mg) or placebo.”
InfluentialFrom the Discovery of GLP-1 to Today’s Diabetes/Obesity Therapy and Beyond
Holst, J. J. (2026) · Biological Psychiatry · doi:10.1016/j.biopsych.2026.04.010 · Cited by 3
Tan, S., Yin, Y., & Lu, J. (2025) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2025.1731127 · Cited by 3
Mora, P., Aroda, V. R., Asong, M., Blüher, M., Heftdal, L. D., Carlander, A. F., Vilsen, L. N., & Rosenstock, J. (2026) · The Lancet · doi:10.1016/s0140-6736(26)01248-1 · Cited by 5
Hsiao, L., Coca, S. G., Fantaye, S. H., Acosta, F. M., & Solis‐Herrera, C. (2025) · Clinical Therapeutics · doi:10.1016/j.clinthera.2025.09.003 · Cited by 2
Wang, S., Fan, D., Yao, Q., & Sun, X. (2025) · Diabetes Obesity and Metabolism · doi:10.1111/dom.16580 · Cited by 3
Renke, G., & Chinellato, L. (2026) · International Journal of Molecular Sciences · doi:10.3390/ijms27093890 · Cited by 3
“It has also demonstrated renoprotective effects in patients with T2DM and nephropathy [34].”
Henao, D. C., Jurado‐Florez, M. A., & Múñoz, Ó. (2024) · Obesity Science & Practice · doi:10.1002/osp4.782 · Cited by 2
“19 In addition, with a baseline GFR of 47.0 � 15.2 mL/min/1.73 m 2 , annual renal function decline was slowed by a mean of 1.16 mL/min/1.73 m 2 (19).”
BackgroundInfluentialDiabetic Kidney Disease: From Pathophysiology to Treatment Perspectives
Varda, L., Vreča, N., Ekart, R., Bevc, S., & Piko, N. (2026) · Kidney & Blood Pressure Research · doi:10.1159/000550085 · Cited by 15
GLP-1 Agonists and Risk of Atrial Fibrillation in Non-Dialysis Chronic Kidney Disease
Dhamelia, P. M., Khandekar, N., Vallurupalli, S., Saucedo, J., Arthur, J. M., Jadvani, D., Beemidi, V. R., & Jain, N. (2026) · Cardiovascular Drugs and Therapy · doi:10.1007/s10557-026-07897-0 · Cited by 2
Six months of physical inactivity is insufficient to cause chronic kidney disease in C57BL/6J micePreprint
Opurum, P. C., Decker, S. T., Stuart, D., Peterlin, A. D., Paula, V. L., Siripoksup, P., Drummond, M. J., Sánchez, A., Ramkumar, N., & Funai, K. (2024) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2024.08.29.610415 · Cited by 2
McKone, D. B., Duprey, K. S., Hall, H. M., Leonhard, A., Schadler, A. D., & Naseman, K. (2025) · Diabetes Spectrum · doi:10.2337/ds24-0035 · Cited by 2
Pecoits‐Filho, R., Kanda, E., Kashihara, N., Ofori‐Asenso, R., Chen, H., Pentakota, S., Järbrink, K., Sánchez, J. J. G., Lam, C. S. P., Fishbane, S. N., et al. (2025) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfaf175 · Cited by 3
Cardiovascular-Kidney-Metabolic Health
Solomon, M., Claudel, S. E., & Verma, A. (2025) · Cardiology Clinics · doi:10.1016/j.ccl.2025.03.001 · Cited by 4
Kishimori, T., Kato, T., Wada, A., Tani, A., Yamaji, R., Koike, J., Iwasaki, Y., Matsumoto, T., Yagi, T., & Okada, M. (2025) · Open Heart · doi:10.1136/openhrt-2025-003382 · Cited by 2
Lingow, S. E., Carris, N. W., Clements, J. N., Courtney, L. A., Lennon, A., Sherrill, C. H., & Dril, E. V. (2025) · JACCP JOURNAL OF THE AMERICAN COLLEGE OF CLINICAL PHARMACY · doi:10.1002/jac5.70111 · Cited by 5
6. Cardio-renal protection in type 2 diabetes
Colagiuri, S., & Ceriello, A. (2025) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2025.112150 · Cited by 6
Nematalla, H. A., Elharoun, M., Sheta, E., Saleh, S. R., Basta, M., Eid, A. H., & EL‐Yazbi, A. F. (2025) · Biochemical Pharmacology · doi:10.1016/j.bcp.2025.117431 · Cited by 3
Yoshida, Y., & Shibata, H. (2025) · Hypertension Research · doi:10.1038/s41440-025-02162-7 · Cited by 2
“…cotransporter 2 (SGLT2) inhibitors, such as empagli fl ozin [8] and dapagli fl ozin [9], and glucagon-like peptide 1 (GLP-1) receptor agonists, including semaglutide [10], have been shown to have renal and cardiovascular protective effects regardless of the presence or absence of diabetes.”
Evaluation and Management of Obesity in Chronic Kidney Disease
Friedman, A. N. (2025) · Journal of Renal Nutrition · doi:10.1053/j.jrn.2025.07.004 · Cited by 4
Advancing Cardiorenal Interaction: From Pathophysiological Paradigms to Novel Therapeutic Strategies
Wei, L., He, P., Gao, J., Huang, L., Zhao, L., Zhang, R., Ning, X., & Sun, S. (2025) · Kidney Diseases · doi:10.1159/000548367 · Cited by 2
“A comprehensive meta-analysis concluded that GLP-1 RAs reduced the risk of MACE by 14%, and composite kidney outcomes by 21% [110].”
Unmasking the silent epidemic: Mortality trends in diabetic nephropathy
Álvarez, M. (2025) · World Journal of Nephrology · doi:10.5527/wjn.v14.i3.108099 · Cited by 3
Ahmad, Y., Wasan, R., Perchik, J. D., & Nanda, N. C. (2026) · Journal of Clinical Medicine · doi:10.3390/jcm15124430 · Cited by 2
“The semaglutide group had a statistically significant lower incidence of the primary composite outcome consisting of kidney failure, a 50% reduction in the glomerular filtration rate from baseline, and death from a kidney or cardiovascular cause [173].”
Zeyfang, A., Wernecke, J., & Bahrmann, A. (2025) · Diabetologie und Stoffwechsel · doi:10.1055/a-2592-8139 · Cited by 3
Gopalakrishnan, U. A., Joshi, A. S., Giri, R., Shah, S. J., Shukla, J., Maheshwari, S., Chowdaiah, R. M., Singh, M. K., Bari, A. S., Pathak, N. P., et al. (2026) · Diabetes Obesity and Metabolism · doi:10.1111/dom.70891 · Cited by 3
Tu, Y., & Yu, H. (2025) · Metabolism and Target Organ Damage · doi:10.20517/mtod.2024.99 · Cited by 5
Ozempic keeps wowing: trial data show benefits for kidney disease
Fairbank, R. (2024) · Nature · doi:10.1038/d41586-024-01564-w · Cited by 2
Aroda, V. R., Davies, M. J., Maaske, J., Millegård, M., Juan, V. L., Aberle, J., Ciudin, A., McCrimmon, R. J., Eklund, O., Shih, J. L., et al. (2026) · The Lancet · doi:10.1016/s0140-6736(26)00802-0 · Cited by 6
Representation of women in randomized controlled trials of novel antidiabetic drugs: A cohort study
Aharon‐Hananel, G., Cohen, Y., & Tau, N. (2024) · Diabetes Obesity and Metabolism · doi:10.1111/dom.15942 · Cited by 2
The User’s Guide to the Pharmacologic Glycemic Management of Type 2 Diabetes in Adults---2024 Update
Butalia, S., BAJAJ, H. S., Jain, R., Leung, K., Mansell, K. D., Reichert, S. M., Senior, P. A., & Shah, B. R. (2024) · Canadian Journal of Diabetes · doi:10.1016/j.jcjd.2024.08.003 · Cited by 4
Alshaikh, A., Alshehri, A., Alzubaidi, L. M. Y., Elbadawi, H., Alsaeed, A. H., Almehthel, M. S., Aldahash, R., Alsabaan, F., Alotaibi, M. S., Alghamdi, K. A., et al. (2025) · Diabetes Therapy · doi:10.1007/s13300-025-01826-4 · Cited by 2
“In addition, the FLOW study showed that semaglutide reduced the risk of clinically important kidney outcomes and death from cardiovascular causes in patients with T2DM and CKD [52, 53].”
Spagnolo, M., & Capodanno, D. (2025) · European Journal of Preventive Cardiology · doi:10.1093/eurjpc/zwaf358 · Cited by 2
Gallwitz, B., Aberle, J., Birkenfeld, A. L., KELLERER, M., Klein, H. H., Landgraf, R., Müller‐Wieland, D., Müssig, K., Nauck, M. A., Siegel, E. G., et al. (2025) · Diabetologie und Stoffwechsel · doi:10.1055/a-2592-7923 · Cited by 4
Updates in chronic kidney disease management: A systematic review
Ammar, A., Edwin, S. B., Whitney, R., Lipari, M., & Giuliano, C. A. (2025) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1002/phar.70014 · Cited by 3
Kidney and Survival Benefits of Semaglutide in Diabetes With Chronic Kidney Disease
Tuttle, K. R., Bakris, G. L., Baeres, F. M. M., Bang, C. N., Bax, W. A., Belmar, N., Musinga, D., Cherney, D. Z. I., Chernin, G., Lim, S. K., et al. (2026) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2026.02.5125 · Cited by 2
Self-citationDecker, S. R. D. R., Chaudhary, R. S., Inoue, K., Song, Y., Ndumele, C. E., Khan, S. S., & Kazi, D. S. (2025) · Diabetes Care · doi:10.2337/dc25-1619 · Cited by 3
Semaglutide for Alzheimer's disease after evoke and evoke+
Schneider, L. S. (2026) · The Lancet · doi:10.1016/s0140-6736(26)00514-3 · Cited by 3
Repetti, G. G., Abel, E. D., Tontonoz, P., & Sallam, T. (2026) · Circulation Research · doi:10.1161/circresaha.126.328680 · Cited by 3
Shokravi, A., Seth, J., & Mancini, G. J. (2026) · Cardiovascular Diabetology · doi:10.1186/s12933-026-03113-3 · Cited by 8
“Semaglutide is the most extensively studied GLP-1RA, with multiple trials, including SUSTAIN-6, PIONEER-6, FLOW, and SOUL [20–22, 31 ] , collectively establishing a robust evidence”
Ferreira, J. P., Mendonça, L., & Neves, J. S. (2024) · Journal of Cardiac Failure · doi:10.1016/j.cardfail.2024.05.006 · Cited by 2
Lai, S., Feng, Y., Li, L., Zhao, J., Wang, Z., & Wang, Y. (2025) · Diabetology & Metabolic Syndrome · doi:10.1186/s13098-025-01866-7 · Cited by 2
“Accumulating evidence also supports the benefits of GLP1RAs in T2D with chronic kidney disease [8, 9] and neuro-cognitive disorders [10].”
Ouimet, J.-P., Mohsen, M., Ni, H., Weisman, A., Udell, J. A., & Cherney, D. Z. I. (2025) · Canadian Journal of Kidney Health and Disease · doi:10.1177/20543581251380509 · Cited by 4
Metadata
- Authors
- Perkovic, V., Tuttle, K. R., Rossing, P., Mahaffey, K. W., Mann, J. F. E., Bakris, G., Baeres, F. M. M., Idorn, T., Bosch-Traberg, H., Lausvig, N. L., & Pratley, R.
- Affiliations
- University of Copenhagen (DK)
- Novo Nordisk A/S, Søborg, Denmark.
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2024-07-11
- Volume
- 391
- Issue
- 2
- Pages
- 109-121
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W4398781461
- Cited by
- 2,099
- References
- 23
- Citations by year
- 2026: 953 · 2025: 863 · 2024: 281
- FWCI
- 551.63
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Research at the University of Copenhagen (University of Copenhagen) (publishedVersion)
- Digital Access to Libraries (submittedVersion)
- IRIS Research product catalog (Sapienza University of Rome) (submittedVersion)
- Funders
- Novo Nordisk A/S
- Topics
- Health Sciences › Medicine › Nephrology › Chronic Kidney Disease and Diabetes
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Nephrology › Acute Kidney Injury Research
- Keywords
- semaglutide, chronic kidney disease, type 2 diabetes, renal failure, estimated glomerular filtration rate decline, cardiovascular mortality, albuminuria, GLP-1 receptor agonists, renal protection, cardiovascular outcomes, albumin-creatinine ratio, kidney transplantation, dialysis, anemia of chronic kidney disease, diabetic nephropathy, SGLT2 inhibitors
- MeSH terms
- Glucagon-Like Peptide-1 Receptor Agonists, Semaglutide, Aged, Cardiovascular Diseases, Diabetes Mellitus, Type 2, Diabetic Nephropathies, Double-Blind Method, Glucagon-Like Peptides, Female, Glomerular Filtration Rate, Humans, Hypoglycemic Agents, Injections, Subcutaneous, Male, Middle Aged, Renal Insufficiency, Chronic
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.